The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 28, 2025

Filed:

Mar. 19, 2019
Applicant:

Multivir Inc., Houston, TX (US);

Inventors:

Robert E. Sobol, Houston, TX (US);

Kerstin B. Menander, Houston, TX (US);

Dora Wiederhold, Houston, TX (US);

Sunil Chada, Houston, TX (US);

Assignee:

Multivir Inc., Houston, TX (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/47 (2006.01); A61K 35/768 (2015.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); C07K 14/54 (2006.01); C12N 15/86 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07K 14/4746 (2013.01); A61K 35/768 (2013.01); A61K 48/005 (2013.01); A61P 35/00 (2018.01); C07K 14/54 (2013.01); C12N 15/86 (2013.01); A61K 9/0019 (2013.01); A61K 45/06 (2013.01); C12N 2710/10343 (2013.01); C12N 2710/24143 (2013.01);
Abstract

Provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of at least one CD 122/CD 132 agonist, at least one immune checkpoint inhibitor and a viral composition comprising one or more viruses engineered to overexpress a tumor suppressor gene and/or an adenoviral death protein. Also provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of at least one oncolytic viral composition and at least one CD122/CD132 agonist and at least one immune checkpoint inhibitor. Also provided herein are methods of enhancing anti-tumor efficacy by administering the agents described above in combination with other cancer therapies. In highly aggressive forms of cancer, known to be generally resistant to immune therapies, these treatments unexpectedly resulted in complete tumor remissions and curative outcomes.


Find Patent Forward Citations

Loading…